

MATERIALS TRANSFER FORM INSTRUCTIONS

Questions regarding this form should be directed to the appropriate DRDA project representative or call DRDA information at 764-5500.

PROPOSAL TYPE

Check the category that best describes the nature of the proposed activity.

SUBMITTED TO

Indicate the name of the company or institution (provider) from which the materials are requested and the name and phone number of your contact in the company or institution, if available.

PROJECT DIRECTOR

The primary or host unit of the proposed project should be identified. The person designated by the unit chair, director, or dean to be responsible for the administrative and programmatic aspects of the proposed project should meet the requirements necessary to serve as Project Director of a sponsored research project.

PROPOSED TIME PERIOD

Indicate the start and end dates proposed for the entire project period.

COST OR FEE FOR MATERIALS

If the provider of materials shown in (1) is also providing funds to conduct the research, do not use this form. Use the Proposal Approval Form. (PAF)

USE OF HUMAN SUBJECTS

For research involving human beings as subjects, a project plan and protocol must be submitted to the IRB committee. This committee must approve the proposal before it is sent to the sponsor or before research is started.

USE OF VERTEBRATE ANIMALS

Approval must be secured from the University Committee on the Use and Care of Animals for any proposed activity involving vertebrate animals during the proposed project period. The Committee can be reached at 763-8028.

USE OF HUMAN PLURIPOTENT STEM CELLS

Approval must be obtained from the Human Pluripotent Stem Cell Research Oversight (HPSCRO) Committee for any proposed activity involving the derivation or use of human embryonic stem cells, and the derivation and use of induced pluripotent stem cells. Further information can be obtained by calling the Committee at 615-8936 or online at: <http://www.research.umich.edu/policies/um/ESCells.html>

RECOMBINANT DNA

Please specify any recombinant DNA that will be used in this project. Regulated recombinant DNA research is specified in the most current edition of the "NIH Guidelines for Recombinant DNA Research," available from the Office of the Vice President for Research (936-3934). Questions concerning recombinant DNA should be directed to this office.

REGENTS' POLICY ON OPENNESS OF RESEARCH

Prompt consultation between the project director and the DRDA project representative is necessary when either discovers a sponsor's intent to impose a restriction on the openness of the sponsored agreement or research results. Often such proposed restrictions can be eliminated through negotiations.

The Regents' policy requires no special justification or documentation procedures for sponsor imposed restrictions that fall within a defined set of "standard" restrictions. Explicit review, justification, and documentation is required for the two categories: non-standard restrictions and classified research restrictions.

A Supplementary Proposal Approval Form R must be submitted for review of restrictions that fall in either the "non-standard" or "classified" categories. The review must be completed prior to acceptance of an award involving such restrictions. Copies of these forms as well as the Regental policy and implementing procedures are available from DRDA project representatives.

CONFLICT OF INTEREST

A conflict of interest may take many forms, but arises when a staff member, in relationship to an outside organization, is in a position to influence the university's business, research, or other decisions in ways that could lead directly or indirectly to financial gain for the staff member or the staff member's family, or give improper advantage to others to the university's detriment.

The University will exercise care in accepting or entering into sponsored agreements in which the faculty investigators or professional staff involved (or, to their knowledge, their spouses, or dependents) have interests that create conflicts. Such agreements will not be accepted if the conflict:

- a) can be expected with reasonable certainty to compromise the integrity of those investigations or undermine the employees' obligations to the University, to the sponsor, or to students, and
(continued on next page)

(continued from previous page)

b) cannot be satisfactorily managed with appropriate administrative oversight.

By signing on line #10 of the PAF, the Principal Investigator certifies that he/she has read and understood the University's policy on financial conflicts of interest in sponsored projects and technology transfer and, to the best of his/her knowledge, has made all required financial disclosures. Should the outside financial or managerial interests of the PI. Or those of his/her spouse or dependents, change during the next calendar year, the PI further agrees to submit a revised DISCLOSURE and CERTIFICATION.

USE OF RADIOISOTOPES IN OR ON HUMANS

The use of radioisotopes in or on humans must be approved by the University Institutional Review Board (IRB) and the Radioactive Drug Research Committee (RDRC) / Subcommittee on the Human Use of Radioisotopes (SHUR). Radiation Safety Services (RSS) as the recipient of RDRC/SHUR human use applications.

USE OF RADIOACTIVE MATERIALS

Authorized users of radioactive material must be approved by the U-M Radiation Policy Committee (RPC) in accordance with the conditions of the University's broad scope license issued by the Nuclear Regulatory Commission. The RPC is responsible for evaluating and approving the users, facilities, protocols, and policies of radioactive material and radiation-producing device use. Radiation Safety Service/OSEH is responsible for ensuring the radiological safety and regulatory compliance of such uses.

HUMAN BODY SUBSTANCES

Please specify any human body substances to be used in this project. Human body substances include: blood, products, all body fluids, organs, tissues, and all pathological materials. Regulated use of these substances is specified in the most recent edition of the "MDOL Bloodborne Pathogens Standard," available from UM OSEH. Questions concerning human body substances should be directed to the UM OSEH Biological Safety Officer at 763-6973.

ETIOLOGIC AGENTS

Please specify any etiologic agents to be used in this project. Etiological agents can produce infectious disease in plants and/or animals (including humans). Regulated etiologic agent research is specified in the most current edition of the "CDC/NIH Guidelines for Research in Microbiological and Biomedical Laboratories." Questions regarding etiologic agents should be directed to the UM-OSEH Biological Safety Officer at 763-6973.

PROPRIETARY MATERIALS

Proprietary materials can include trade secrets, business data, or technical or scientific information that the project director, University, or the sponsor claim as confidential and/or proprietary. Project directors who need to include proprietary material in their proposal or to protect such material in their project should contact their DRDA project representative immediately.

SEED MONEY/PILOT PROJECT

If this proposal resulted from any seed money or a pilot project funded by the University, please indicate the source of the funding and the amount received. These data enable a review of the success and importance of seed money.

WORK OFF-CAMPUS

Please indicate if the project will be conducted off University property. If any work is to take place in a foreign country, please indicate the country.

INSUFFICIENT SPACE

The DRDA project representative should be contacted as soon as possible if sufficient space is not available to carry out the proposed project. Some rental space may be available from Plant Extension. If rental space is committed, a representative from Plant Extension should sign the approval on this form.

UNIVERSITY SPACE

Indicate the room(s) and building(s) where the proposed activities will occur. This space commitment should be reviewed and approved by the dean or director responsible for the space.